Neurovalens

Neurovalens, founded in 2014 in Belfast, is a commercial-stage medical device company focused on non-invasive neurostimulation. Its core technology platform uses electrical vestibular nerve stimulation (VeNS) to modulate brain activity, with its first FDA-cleared product, Modius Sleep, targeting chronic insomnia. The company has secured regulatory approvals in the US, UK, and EU, is expanding its pipeline into weight management, and has raised significant venture funding to support growth. Neurovalens positions itself as a digital health leader offering alternatives to pharmaceuticals for neurological and metabolic conditions.

Non-invasive transcutaneous electrical vestibular nerve stimulation (VeNS) delivered via a wearable headset to modulate brainstem and hypothalamic activity.

Neurovalens competes in the digital therapeutic and medical device space for neurology and metabolism. Direct competitors include other prescription digital therapeutics for insomnia (e.g., Somryst) and weight management, as well as non-invasive neuromodulation devices from companies like Fisher Wallace. It also competes indirectly with pharmaceutical sleep aids and GLP-1 agonists for weight loss.